E2/LNG oral (Wellnara, BAY86-5029)
Pre-clinicalCompleted 0 watching 0 views this week๐ค Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Postmenopause
Conditions
Postmenopause
Trial Timeline
Sep 1, 2007 โ May 1, 2009
NCT ID
NCT00913926About E2/LNG oral (Wellnara, BAY86-5029)
E2/LNG oral (Wellnara, BAY86-5029) is a pre-clinical stage product being developed by Bayer for Postmenopause. The current trial status is completed. This product is registered under clinical trial identifier NCT00913926. Target conditions include Postmenopause.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01401114 | Pre-clinical | Completed |
| NCT00913926 | Pre-clinical | Completed |
Competing Products
16 competing products in Postmenopause